Shareholders in STENOCARE A/S nominate new member to the Board of Directors

Today, STENOCARE announces that its major shareholders plan to nominate Mr. Ian Abramowitz to the Board of Directors, further strengthening its international cannabis expertise.

Mr. Abramowitz is the Senior Vice President of Global Investments & Partnerships at CannTrust Inc, a leading Canadian producer of medical cannabis. His significant experience in the medical cannabis industry includes serving as CannTrust’s CFO from 2016 to 2018. In this role, Mr. Abramowitz was a key member of the executive team who were instrumental in building CannTrust’s patient count from 10,000 in December 2016 to 58,000 in December 2018, increasing top-line annual revenue from Cad$ 4,5mill to Cad$ 45,6mill and leading CannTrust’s public listing on the Canadian Securities Exchange (“CSE”), the Toronto Stock Exchange (“TSX”) and most recently the New York Stock Exchange (“NYSE”).

Marianne Wier, Chairman of the Board comments:

“I look forward to welcoming Ian Abramowitz to the STENOCARE Board of Directors. His deep medical cannabis industry insight will supplement the current competencies in the Board, and we will also be able to leverage his knowledge from the fantastic CannTrust journey”

Ian Abramowitz, CannTrust Senior Vice President, Global Investments & Partnerships, comments:

“I am honored to join the Board of Directors of STENOCARE and be part of the exciting growth that is ahead. I see many similarities between the journey of CannTrust and STENOCARE, and am looking forward to realizing the market potential together with the board and management team”

STENOCARE’s four largest shareholders – representing 75% of total votes – have communicated their support for electing Mr. Abramowitz, thereby increasing board membership from four to five members when Mr. Abramowitz is elected at the Annual General Meeting on the 16thof May 2019.

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO          Phone: +45 31770060            E-mail: presse@stenocare.com

STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot program. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers high quality medical cannabis oil, which is produced by hygienic and high technology cultivation that comply with the strict Danish regulatory requirements. STENOCARE is also developing a separate production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark